Maleimide Is a Potent Inhibitor of Topoisomerase II in Vitro and in Vivo: A New Mode of Catalytic Inhibition
- 1 May 2002
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 61 (5) , 1235-1243
- https://doi.org/10.1124/mol.61.5.1235
Abstract
Maleimide, N-ethyl-maleimide (NEM), andN-methyl-maleimide (NMM) were identified as potent catalytic inhibitors of purified human topoisomerase IIα, whereas the ring-saturated analog succinimide was completely inactive. Catalytic inhibition was not abrogated by topoisomerase II mutations that totally abolish the effect of bisdioxopiperazine compounds on catalytic inhibition, suggesting a different mode of action by these maleimides. Furthermore, in DNA cleavage assay maleimide and NEM could antagonize etoposide-induced DNA double-strand breaks. Consistently, maleimide could antagonize the effect of topoisomerase II poisons in three different in vivo assays: 1) In an alkaline elution assay maleimide protected against etoposide-induced DNA damage. 2) In a band depletion assay maleimide reduced etoposide-induced trapping of topoisomerase IIα and β on DNA. 3) In a clonogenic assay maleimide antagonized the cytotoxicity of etoposide and daunorubicin on four different cell lines of human and murine origin. at-MDR cell lines with reduced nuclear topoisomerase IIα content are fully sensitive to maleimide, indicating that it is not a topoisomerase II poison in vivo. Our finding that topoisomerase II is sensitive to maleimide, NMM, and NEM but insensitive to succinimide demonstrates a strict requirement for the unsaturated ring bond for activity. We suggest that the observed antagonism in vitro and in vivo is caused by covalent modification of topoisomerase II cysteine residues reducing the amount of catalytically active enzyme sensitive to the action of topoisomerase II poisons.Keywords
This publication has 21 references indexed in Scilit:
- Decreased topoisomerase IIα expression confers increased resistance to ICRF-193 as well as VP-16 in mouse embryonic stem cellsCancer Letters, 2001
- N-terminal and core-domain random mutations in human topoisomerase II α conferring bisdioxopiperazine resistanceFEBS Letters, 2000
- A Novel Mechanism of Cell Killing by Anti-topoisomerase II BisdioxopiperazinesJournal of Biological Chemistry, 2000
- Catalytic inhibitors of DNA topoisomerase IIBiochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 1998
- Merbarone Inhibits the Catalytic Activity of Human Topoisomerase IIα by Blocking DNA CleavageJournal of Biological Chemistry, 1998
- In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabinBritish Journal of Cancer, 1997
- DNA Topoisomerases: Essential Enzymes and Lethal TargetsAnnual Review of Pharmacology and Toxicology, 1994
- Different modes of anthracycline interaction with topoisomerase II: Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistanceBiochemical Pharmacology, 1993
- Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell linesBritish Journal of Cancer, 1993
- In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL)British Journal of Cancer, 1989